May 18, 2018 / 12:06 AM / a year ago

Appeals court nixes Mallinckrodt patent on respiratory treatment

A federal appeals court on Wednesday invalidated a patent relating to Mallinckrodt Pharmaceuticals’ blood vessel dilator Inomax, helping clear the way for Praxair Inc to launch a copycat version.

The U.S. Court of Appeals for the Federal Circuit affirmed a determination by the Patent Trial and Appeal Board that key claims in a patent covering a method of distributing Inomax’s active ingredient nitric oxide were invalid as obvious.

To read the full story on Westlaw Practitioner Insights, click here:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below